11:50 AM EDT, 05/31/2024 (MT Newswires) -- (Updates with details in second, third paragraphs)

Moderna ( MRNA ) said Friday that the US Food and Drug Administration has approved its mRESVIA vaccine against lower respiratory tract disease caused by respiratory syncytial virus infection in adults aged 60 years and older.

The approval was based on positive data from a global phase 3 trial, where a vaccine efficacy of 83.7% was demonstrated against respiratory syncytial virus lower respiratory tract disease, based on a patient population of about 37,000 adults ages 60 years or older, said the company.

Moderna ( MRNA ) said it expects to have mRESVIA available to eligible patients in the US by the 2024/2025 respiratory virus season.

Price: 146.73, Change: -4.76, Percent Change: -3.14